FLAP
FLAP (5-lipoxygenase activating protein) is an integral protein within the nuclear membrane and is necessary for the activation of 5-lipoxygenase and therefore for the production of leukotrienes.
Products Related to FLAP(10)
- GC12232BAY-X 1005CAS: 128253-31-6Purity: >98.50%
BAY-X 1005 (BAY X 1005; DG-031) is an orally active and selective 5-lipoxygenase activating protein (FLAP) inhibitor.
- GC15506GSK2190915 sodium saltCAS: 1196070-26-4Purity: >99.00%
GSK2190915 sodium salt (GSK2190915; AM-803) is a potent and orally bioavailable 5-lipoxygenase-activating protein (FLAP) inhibitor with a potency of 2.9 nM in FLAP binding, an IC50 of 76 nM for inhibition of LTB4 in human blood.
- GC31689Fiboflapon (GSK2190915)CAS: 936350-00-4Purity: >98.50%
Fiboflapon (GSK2190915) (GSK2190915; AM-803) is a potent and orally bioavailable 5-lipoxygenase-activating protein (FLAP) inhibitor with a potency of 2.9 nM in FLAP binding, an IC50 of 76 nM for inhibition of LTB4 in human blood.
- GC37059Quiflapon sodiumCAS: 147030-01-1Purity: >98.50%
Quiflapon sodium (MK-591 sodium) is a selective and specific 5-Lipoxygenase-activating protein (FLAP) inhibitor.
- GC62422AtuliflaponCAS: 2041075-86-7Purity: >98.00%
Atuliflapon (AZD5718) is an orally active inhibitor of FLAP (5?Lipoxygenase activating protein), with an IC50 of 2 nM.
| Catalog No. | Product Name | CAS No. | Purity | Structure |
|---|---|---|---|---|
| GC11457 | MK-0591 | 136668-42-3 | >99.00% | |
An inhibitor of FLAP | ||||
| GC12232 | BAY-X 1005 | 128253-31-6 | >98.50% | |
BAY-X 1005 (BAY X 1005; DG-031) is an orally active and selective 5-lipoxygenase activating protein (FLAP) inhibitor. | ||||
| GC12277 | MK 886 | 118414-82-7 | >99.50% | |
MK 886 is a 5-lipoxygenase-activating protein (FLAP) inhibitor and PPARα antagonist (IC 50 =30nM). | ||||
| GC15506 | GSK2190915 sodium salt | 1196070-26-4 | >99.00% | |
GSK2190915 sodium salt (GSK2190915; AM-803) is a potent and orally bioavailable 5-lipoxygenase-activating protein (FLAP) inhibitor with a potency of 2.9 nM in FLAP binding, an IC50 of 76 nM for inhibition of LTB4 in human blood. | ||||
| GC31689 | Fiboflapon (GSK2190915) | 936350-00-4 | >98.50% | |
Fiboflapon (GSK2190915) (GSK2190915; AM-803) is a potent and orally bioavailable 5-lipoxygenase-activating protein (FLAP) inhibitor with a potency of 2.9 nM in FLAP binding, an IC50 of 76 nM for inhibition of LTB4 in human blood. | ||||
| GC31839 | AM 103 | 1147872-22-7 | >98% | |
AM 103 is a potent and selective FLAP inhibitor, with an IC50 value of 4.2 nM. | ||||
| GC37059 | Quiflapon sodium | 147030-01-1 | >98.50% | |
Quiflapon sodium (MK-591 sodium) is a selective and specific 5-Lipoxygenase-activating protein (FLAP) inhibitor. | ||||
| GC62422 | Atuliflapon | 2041075-86-7 | >98.00% | |
Atuliflapon (AZD5718) is an orally active inhibitor of FLAP (5?Lipoxygenase activating protein), with an IC50 of 2 nM. | ||||
| GC69101 | FEN1-IN-2 | 824983-94-0 | >98% | |
FEN1-IN-2 (compound 20) is an inhibitor of flap endonuclease 1 (FEN1), with IC50 values of 3 nM and 226 nM for FEN1 and XPG, respectively. | ||||
| GC73487 | FEN1-IN-5 | 824983-93-9 | >99.00% | |
FEN1-IN-5 (compound 12A) is a potent inhibitor of Flap endonuclease-1 (FEN1, IC50=12 nM), involving in DNA repair. | ||||
